Zydus Therapeutics, Zydus Lifesciences, Saroglitazar, Primary Biliary Cholangitis, PBC, EPICS-III Trial, Clinical Trial, Liver Disease, Hepatology, Alkaline Phosphatase, ACG 2026, PPAR Agonist

Nashville, Tennessee, U.S., October 12, 2026 Zydus Therapeutics has presented a new post-hoc analysis of the Phase III EPICS-III...